Gene Therapy for Mutations in the IQSEC2 Gene

This is a compelling summary of a gene therapy approach for IQSEC2-related disorders. Given the severity of the phenotype—particularly the drug-resistant epilepsy and intellectual disability—the transition from knockout mouse models to potential human clinical trials is a significant milestone.

The success of the adeno-associated virus (AAV) in normalizing the seizure threshold and correcting behavioral abnormalities suggests that even in a complete absence of the protein (knockout), the cellular machinery remains receptive to exogenous replacement.

The X-Linked Factor

Since boys have only one X chromosome (XY), a mutation in the IQSEC2 gene means they have no working copy of the protein. This is why the symptoms (seizures, intellectual disability) are often so severe in boys.

Girls have two X chromosomes (XX). If one has the mutation, the other usually has a healthy version of the gene. However, due to a process called X-inactivation, some cells will use the healthy gene and others will use the mutated one. This often results in a wider range of symptoms in females—some may be severely affected, while others have milder learning or behavioral challenges.